Moreover, the AKT activity (p-AKT) was greatly decreased in 2.0 mg/g dasatinib-treated tumor by 85% and slightly decreased in 0.5 mg/g dasatinib-treated group by 10% (Figure 4, left panel). Here, AKT1 is linked to neoplasm.